Autoantibodies in inflammatory myopathies

American Journal of the Medical Sciences

Volumn 319, Issue 4, 2000, Pages 227-233

  Garlepp, M J ^a,b   Mastaglia, F L ^b,c  

^a CURTIN UNIVERSITY   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

CONFERENCE PAPER; DERMATOMYOSITIS; HUMAN; INCLUSION BODY MYOSITIS; INFLAMMATION; MIXED CONNECTIVE TISSUE DISEASE; MYOPATHY; PATHOGENESIS; POLYMYOSITIS; SJOEGREN SYNDROME;

EID: 0034130420     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200004000-00005     Document Type: Conference Paper

References (57)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med 1991;325:1487-98.
2. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855-9.
3. Orimo S, Koga R, Goto K, et al. Immunohistochemical analysis of perforin and granzyme A in inflammatory myopathies. Neuromuscul Disord 1994;4:219-26.
4. Goebels N, Michaelis D, Engelhart M, et al. Differential expression of perforin in muscle infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996;97:2905-10.
5. Garlepp MJ, Mastaglia FL. Inclusion body myositis. J Neurol Neurosurg Psychiatr 1996;33:1240-5.
6. Whitaker JN, Engel WK. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med 1972;286:333-8.
7. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329-34.
8. Stein DP, Jordan SC, Toyoda M, et al. Anti-endothelial cell antibodies (AECA) in dermatomyositis (DM) [abstract]. Neurology 1993;43:A356.
9. Salojin KV, Bordron A, Nassonov EL, et al. Anti-endothelial cell antibody, thrombomodulin, and von Willebrand factor in idiopathic inflammatory myopathies. Clin Diagn Lab Immunol 1997;4:519-21.
10. Targoff IN. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 1993;100:116S-123S.
11. Miller FW, Waite KA, Biswas T, et al. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci USA 1990;87:9933-7.
12. Mimori T. Structures targeted by the immune system in myositis. Curr Opin Rheumatol 1996;8:521-7.
13. Hollingsworth PN, Garlepp MJ, Dawkins RL. Autoimmune diseases of muscle. In: Rose NR, Mackay IR, editors. The autoimmune diseases. 3rd ed. Orlando: Academic Press; 1998. p. 663-86.
14. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity. Nature 1983;160:420-34.
15. Goldstein R, Duvic M, Targoff IN, et al. HLA-D region genes associated with autoantibody responses to histidyl-transfer RNA synthetase (Jo-1) and other translation-related factors in myositis. Arthritis Rheum 1990;33:1240-8.
16. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-74.
17. Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diag Lab Immunol 1995;2:1-9.
18. Martin A, Shulman MJ, Tsui FWL. Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis. FASEB J 1995;9:1226-33.
19. Hirakata M, Nakamura K, Okano Y, et al. Anti-alanyl tRNA synthetase (PL-12) antibodies are associated with interstitial lung diseases in Japanese patients. Arthritis Rheum 1995;38:S321.
20. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Sem Arthritis Rheum 1996;26:459-67.
21. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33:1361-70.
22. Nilasena DS, Trieu EP, Targoff IN. Analysis of the Mi-2 autoantigen in dermatomyositis. Arthritis Rheum 1995;38: 123-8.
23. Seelig HP, Moosbrugger I, Ehrfeld H, et al. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995;38:1389-99.
24. Dvir A, Peterson SR, Knuth MW, et al. Ku autoantigen is the regulatory component of a template-dependent protein kinase that phosphorylates RNA polymerase II. Proc Natl Acad Sci U S A 1992;89:11920-4.
25. Von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Sem Arthritis Rheum 1995; 24:323-58.
26. Hausmanowa-Petrusewicz I, Kowalska-Oledzka E, Miller FW, et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:1257-66.
27. Suwa A, Hirakata M, Takeda Y, et al. Autoantibodies to DNA-dependent protein kinases: probes for the catalytic subunit. J Clin Invest 1996;97:1417-21.
28. Marguerie C, Bunn CC, Copier J, et al. The clinical significance and immunogenetic features of patients with autoantibodies to nucleolar antigen Pm-Scl. Medicine 1992; 71:327-36.
29. Oddis CV, Okano Y, Rudert WA, et al. Serum autoantibody to the nucleolar antigen PM-Scl. Arthritis Rheum 1992; 35:1211-7.
30. Reimer G, Scheer U, Peters JM, et al. Immunolocalisation and partial characterisation of a nucleolar autoantigen (Pm-Scl) associated with polymyositis/scleroderma overlap syndrome. J Immunol 1986;137:3802-8.
31. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.
32. Arad-Dann H, Isenberg DA, Ovadia E, et al. Autoantibodies against a nuclear 56kD protein: a marker for inflammatory muscle disease. J Autoimmunity 1989;2:877-88.
33. Cambridge G, Ovadia E, Isenberg DA, et al. Juvenile dermatomyositis: serial studies of circulating autoantibodies to a 56kD nuclear protein. Clin Exp Rheumatol 1994;12: 451-7.
34. Feist E, Dorner T, Kuckelkorn U, et al. Proteasome α-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med 1996;184:1313-8.
35. Rutjes SA, Vree Egberts WT, Jongen P, et al. Ant-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
36. Vasquez-Abad D, Rothfield NF. Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis. Arthritis Rheum 1996;39:292-6.
37. Rider LG, Miller FW, Targoff IN, et al. A broadened spectrum of juvenile myositis: myositis-specific autoantibodies in children. Arthritis Rheum 1994;37:1534-8.
38. Schnitz W, Taylor-Albert E, Targoff IN, et al. Anti-Pm/ Scl autoantibodies in patients without clinical polymyositis or scleroderma. J Rheumatol 1996;23:1729-33.
39. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990;27:343-56.
40. Spuler S, Engel AG. Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies. Neurology 1998;50:41-6.
41. Germain RN. MHC-dependent antigen processing and peptide presentation providing ligands for T lymphocyte activation. Cell 1994;76:287-9.
42. Kalovidouris AE. The role of cell mediated immunity in polymyositis. Curr Opin Rheumatol 1991;3:911-8.
43. Karpati G, Carpenter S. Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993;2:527-56.
44. Blechynden LM, Lawson MA, Tabarias H, et al. Myositis induced by naked DNA immunisation with the gene for histidyl-tRNA synthetase. Hum Gene Ther 1997;8:1469-80.
45. Gelpi C, Martinez MA, Vidal S, et al. Autoantibodies to a transfer RNA-associated protein in a murine model of chronic graft versus host disease. J Immunol 1994;152:1989-99.
46. Stuhlmuller B, Jerez, R, Hausdorf G, et al. Novel autoantibodies against muscle-cell membrane proteins in patients with myositis. Arthritis Rheum 1996;39:1860-8.
47. Alarcon-Segovia D, Ruiz-Arguelles A, Llorente L. Broken dogma: penetration of autoantibodies into living cells. Immunol Today 1996;17:163-4.
48. Lenk RP, Maizel JV, Crouch RJ. Expression of two late adenovirus genes is altered by introducing antibodies against ribonucleoprotein into living cells. J Biochem 1982;121:475-82.
49. Arnett FC, Targoff IN, Mimori T, et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996;39:1507-18.
50. Reveille JD, MacLeod MJ, Whittington K, et al. Specific amino acid residues in the hypervariable region of HLA-DQA1 and DQB1 chain genes promote the Ro (SS-A)/La (SS-B) autoantibody responses. J Immunol 1991;146: 3871-6.
51. Miller FW. Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies. JAMA 1993; 270:1846-9.
52. Hirakata M, Nakamura K, Fujii T, et al. Clinical and immunogenetic features of anti-SRP autoantibodies in Japanese patients. Arthritis Rheum 1995;38:S321.
53. Mierau R, Dick T, Bartz-Bazzanella P, et al. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum 1996;39:868-76.
54. Hirakata M, Suwa A, Nakamura K, et al. Myositis-specific antibodies are associated with HLA class II alleles in Japanese patients. Arthritis Rheum 1995;38:S321.
55. Kaneoka H, Hsu K-C, Takeda Y, et al. Molecular genetic analysis of HLA-DR and HLA-DQ genes among anti-U1-70kD autoantibody positive connective tissue disease patients. Arthritis Rheum 1992;35:83-94.
56. Dong R-P, Kimura A, Hashimoto H, et al. Difference in HLA-linked genetic background between mixed connective tissue disease and systemic lupus erythematosus. Tissue Antigens 1993;41:20-5.
57. Garlepp MJ. Genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1996;8:514-20.